Pharmacoeconomic review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen biopharmaceuticals Canada, Inc.) indication, for the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older

AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injectio...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, August 2018
Edition:	Version: Final with redactions
Series:	CADTH common drug review
Subjects:	Child Canada Muscle Spasticity / Drug Therapy Cost-benefit Analysis Neuromuscular Agents / Therapeutic Use Botulinum Toxins, Type A / Therapeutic Use Lower Extremity
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK540203
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa